N	Concordance
1	nisms of resistance to alkylating agent melphalan (Mel) in leukemia cell and to 
2	on with tumor necrosis factor-alpha and melphalan on pulmonary function assessme
3	her hand, dacarbazine, chlorambucil and melphalan are non-porphyrinogenic. We al
4	y).  An oral chemotherapy drug known as melphalan combined with anoral steroid (
5	eated or treated with cyclophosphamide, melphalan, taxol or cisplatin. Tumor oxy
6	feasibility and toxicities of high-dose melphalan (L-PAM) and busulfan/cyclopho
7	f thermosensitive-liposome-encapsulated melphalan and radiation in murine melano
8	ing two cycles of high-dose intravenous melphalan (70 mg/m2). A relapse occurred
9	al of maintenance versus no maintenance melphalan and prednisone in responding m
10	ross-resistance to the nitrogen mustard melphalan but maintained the same sensit
11	escence detection. The concentration of melphalan in perfusate and tissues was l
12	the tissue and perfusate time course of melphalan after melphalan perfusion. App
13	ells. From these results enhancement of melphalan cytotoxicity mediated by NO ap
14	ination chemotherapy is not superior to melphalan and prednisolone even in high 
15	 times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide